SAFETY, FEASIBILITY OF INTRAVENOUS AND INTRATHECAL INJECTION OF AUTOLOGOUS BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: AN OPEN LABEL PHASE I CLINICAL TRIAL

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

NABAVI SEYED MASSOOD; ARAB LEILA; JAROOGHI NEDA; BOLURIEH TINA; ABBASI FATEMEH; MARDPOUR SOURA; AZIMYIAN VAJIHE; MOEININIA FATEMEH; MAROUFIZADEH SAMAN; SANJARI LEILA; HOSSEINI SEYEDEH ESMAT; AGHDAMI NASSER

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Cell Journal (Yakhteh) Year:2019 | Volume:20 | Issue:4 Page(s): 592-598

Download Full-Text

View:

338

Download:

285

Cites:

Information Journal Paper

Title

SAFETY, FEASIBILITY OF INTRAVENOUS AND INTRATHECAL INJECTION OF AUTOLOGOUS BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: AN OPEN LABEL PHASE I CLINICAL TRIAL

Author(s)

Keywords

AMYOTROPHIC LATERAL SCLEROSIS

BONE MARROW

INTRATHECAL

INTRAVENOUS

MESENCHYMAL STROMAL CELL

Abstract

Objective: AMYOTROPHIC LATERAL SCLEROSIS (ALS) is the most severe disorder within the spectrum of motor neuron diseases (MND) that has no effective treatment and a progressively fatal outcome. We have conducted two clinical trials to assess the safety and feasibility of INTRAVENOUS (IV) and INTRATHECAL (IT) injections of BONE MARROW derived MESENCHYMAL STROMAL CELLs (BM-MSCs) in patients with ALS.Materials and Methods: This is an interventional/experimental study. We enrolled 14 patients that met the following inclusion criteria: definitive diagnosis of sporadic ALS, ALS Functional Rating Scale (ALS-FRS) ³24, and ³40% predicted forced vital capacity (FVC). All patients underwent BONE MARROW (BM) aspiration to obtain an adequate sample for cell isolation and culture. Patients in group 1 (n=6) received an IV and patients in group 2 (n=8) received an IT injection of the cell suspension. All patients in both groups were followed at 24 hours and 2, 4, 6, and 12 months after the injection with ALS-FRS, FVC, laboratory tests, check list of side effects and brain/spinal cord magnetic resonance imaging (MRI). In each group, one patient was lost to follow up one month after cell injection and one patient from IV group died due to severe respiratory insufficiency and infection.Results: During the follow up there were no reports of adverse events in terms of clinical and laboratory assessments. In MRI, there was not any new abnormal finding. The ALS-FRS score and FVC percentage significantly reduced in all patients from both groups.Conclusion: This study has shown that IV and IT transplantation of BM-derived stromal cells is safe and feasible (Registration numbers: NCT01759797 and NCT01771640).

Cites

No record.

References

No record.

Cite

APA: Copy

NABAVI, SEYED MASSOOD, ARAB, LEILA, JAROOGHI, NEDA, BOLURIEH, TINA, ABBASI, FATEMEH, MARDPOUR, SOURA, AZIMYIAN, VAJIHE, MOEININIA, FATEMEH, MAROUFIZADEH, SAMAN, SANJARI, LEILA, HOSSEINI, SEYEDEH ESMAT, & AGHDAMI, NASSER. (2019). SAFETY, FEASIBILITY OF INTRAVENOUS AND INTRATHECAL INJECTION OF AUTOLOGOUS BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: AN OPEN LABEL PHASE I CLINICAL TRIAL. CELL JOURNAL (YAKHTEH), 20(4), 592-598. SID. https://sid.ir/paper/706599/en

Vancouver: Copy

NABAVI SEYED MASSOOD, ARAB LEILA, JAROOGHI NEDA, BOLURIEH TINA, ABBASI FATEMEH, MARDPOUR SOURA, AZIMYIAN VAJIHE, MOEININIA FATEMEH, MAROUFIZADEH SAMAN, SANJARI LEILA, HOSSEINI SEYEDEH ESMAT, AGHDAMI NASSER. SAFETY, FEASIBILITY OF INTRAVENOUS AND INTRATHECAL INJECTION OF AUTOLOGOUS BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: AN OPEN LABEL PHASE I CLINICAL TRIAL. CELL JOURNAL (YAKHTEH)[Internet]. 2019;20(4):592-598. Available from: https://sid.ir/paper/706599/en

IEEE: Copy

SEYED MASSOOD NABAVI, LEILA ARAB, NEDA JAROOGHI, TINA BOLURIEH, FATEMEH ABBASI, SOURA MARDPOUR, VAJIHE AZIMYIAN, FATEMEH MOEININIA, SAMAN MAROUFIZADEH, LEILA SANJARI, SEYEDEH ESMAT HOSSEINI, and NASSER AGHDAMI, “SAFETY, FEASIBILITY OF INTRAVENOUS AND INTRATHECAL INJECTION OF AUTOLOGOUS BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: AN OPEN LABEL PHASE I CLINICAL TRIAL,” CELL JOURNAL (YAKHTEH), vol. 20, no. 4, pp. 592–598, 2019, [Online]. Available: https://sid.ir/paper/706599/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops